Tumor necrosis factor-alpha and the progression of diabetes in non-obese diabetic mice

Citation
Ea. Green et Ra. Flavell, Tumor necrosis factor-alpha and the progression of diabetes in non-obese diabetic mice, IMMUNOL REV, 169, 1999, pp. 11-22
Citations number
106
Categorie Soggetti
Immunology
Journal title
IMMUNOLOGICAL REVIEWS
ISSN journal
01052896 → ACNP
Volume
169
Year of publication
1999
Pages
11 - 22
Database
ISI
SICI code
0105-2896(199906)169:<11:TNFATP>2.0.ZU;2-6
Abstract
In the past decade, a wealth of information has accumulated through studies in non-obese diabetic (NOD) mice regarding the molecular and cellular even ts that participate in the progression to diabetes in insulin-dependent dia betes mellitus (IDDM). One molecule that has received considerable attentio n is the inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). TNF -alpha has been demonstrated to have a positive or negative effect on the p rogression to diabetes in NOD mice, although the mechanism by which TNF-alp ha exerts these differential outcomes is unknown. Here we describe a new NO D model for analyzing the role of TNF-alpha in IDDM, TNF-alpha-NOD mice. TN F-alpha-NOD mice express TNF-alpha solely in their islets from neonatal lif e onwards, and develop accelerated progression to diabetes. This rapid prog ression to diabetes is related to earlier and more aggressive infiltration of the islets with immune cells and an enhancement in the presentation of i slet antigen in situ in the islets by islet-infiltrating antigen-presenting cells to T cells. Although adoptive transfer studies demonstrated that TNF -alpha can enhance presentation of islet antigen to both effector CD4(+) an d CD8(+) T cells, further investigations in TNF-alpha-NOD mice deficient in either CD4(+) or CD8(+) T cells demonstrated that diabetes progression is dependent on CD8(+) T cells, with CD4(+) T cells playing a lesser role. The data accumulating from TNF-alpha-NOD mice, described in this review, indic ates novel pathways by which inflammatory stimuli can precipitate autoimmun ity, and suggests newer approaches in the design of therapeutic treatments that prevent beta-cell destruction in IDDM.